Fortress Biotech
FBIO
58 hedge funds and large institutions have $27M invested in Fortress Biotech in 2017 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 8 closing their positions.
91% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 11
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
7% more funds holding
Funds holding: 54 → 58 (+4)
0% more ownership
Funds ownership: 0.8% → 0.81% (+0%)
6% less capital invested
Capital invested by funds: $28.8M → $27M (-$1.79M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$604K |
| 2 |
SIM
Spark Investment Management
New York
|
+$473K |
| 3 |
SO
STRS Ohio
Columbus,
Ohio
|
+$469K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$422K |
| 5 |
BlackRock
New York
|
+$395K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$2.87M |
| 2 |
AHB
Abner Herrman & Brock
Jersey City,
New Jersey
|
-$493K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$439K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$102K |
| 5 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$67K |
FBIO Hedge Fund Activity: Q3 2017 in Review
58 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Fortress Biotech (FBIO) for Q3 2017, worth a combined $27M — down 6.2% from $28.8M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new FBIO positions and 8 closed out — a net gain of 4 holders — while 21 added to existing stakes and 11 trimmed.
The largest buyer was Millennium Management, adding an estimated $604K. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $2.87M sold.
- 58 institutional investors held Fortress Biotech (FBIO) as of Q3 2017, up from 54 in Q2 2017.
- Funds reported $27M of Fortress Biotech stock for Q3 2017, down 6.2% quarter-over-quarter.
- 12 funds opened new Fortress Biotech positions in Q3 2017 and 8 closed out, a net change of +4 holders.
- The largest Fortress Biotech buyer in Q3 2017 was Millennium Management, an estimated $604K added.
- The largest Fortress Biotech seller in Q3 2017 was Avoro Capital Advisors, an estimated $2.87M sold.
Based on aggregated 13F filings for Q3 2017.